Back to Search Start Over

Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report

Authors :
Dominguez-Valentin, Mev
Crosbie, Emma J.
Engel, Christoph
Aretz, Stefan
Macrae, Finlay
Winship, Ingrid
Capella, Gabriel
Thomas, Huw
Nakken, Sigve
Hovig, Eivind
Nielsen, Maartje
Sijmons, Rolf H.
Bertario, Lucio
Bonanni, Bernardo
Tibiletti, Maria Grazia
Cavestro, Giulia Martina
Mints, Miriam
Gluck, Nathan
Katz, Lior
Heinimann, Karl
Vaccaro, Carlos A.
Green, Kate
Lalloo, Fiona
Hill, James
Schmiegel, Wolff
Vangala, Deepak
Perne, Claudia
Strauss, Hans-Georg
Tecklenburg, Johanna
Holinski-Feder, Elke
Steinke-Lange, Verena
Mecklin, Jukka-Pekka
Plazzer, John-Paul
Pineda, Marta
Navarro, Matilde
Brunet Vidal, Joan
Kariv, Revital
Rosner, Guy
Alejandra Pinero, Tamara
Laura Gonzalez, Maria
Kalfayan, Pablo
Ryan, Neil
Ten Broeke, Sanne W.
Jenkins, Mark A.
Sunde, Lone
Bernstein, Inge
Burn, John
Greenblatt, Marc
Cappel, Wouter H. de Vos tot Nederveen
Della Valle, Adriana
Lopez-Koestner, Francisco
Alvarez, Karin
Buettner, Reinhard
Goergens, Heike
Morak, Monika
Holzapfel, Stefanie
Hueneburg, Robert
Doeberitz, Magnus von Knebel
Loeffler, Markus
Rahner, Nils
Weitz, Jurgen
Pylvanainen, Kirsi
Renkonen-Sinisalo, Laura
Lepisto, Anna
Auranen, Annika
Hopper, John L.
Win, Aung Ko
Haile, Robert W.
Lindor, Noralane M.
Gallinger, Steven
Le Marchand, Loic
Newcomb, Polly A.
Figueiredo, Jane C.
Thibodeau, Stephen N.
Therkildsen, Christina
Okkels, Henrik
Ketabi, Zohreh
Denton, Oliver G.
Rodland, Einar Andreas
Vasen, Hans
Neffa, Florencia
Esperon, Patricia
Tjandra, Douglas
Moeslein, Gabriela
Sampson, Julian R.
Evans, D. Gareth
Seppala, Toni T.
Moller, Pal
Dominguez-Valentin, Mev
Crosbie, Emma J.
Engel, Christoph
Aretz, Stefan
Macrae, Finlay
Winship, Ingrid
Capella, Gabriel
Thomas, Huw
Nakken, Sigve
Hovig, Eivind
Nielsen, Maartje
Sijmons, Rolf H.
Bertario, Lucio
Bonanni, Bernardo
Tibiletti, Maria Grazia
Cavestro, Giulia Martina
Mints, Miriam
Gluck, Nathan
Katz, Lior
Heinimann, Karl
Vaccaro, Carlos A.
Green, Kate
Lalloo, Fiona
Hill, James
Schmiegel, Wolff
Vangala, Deepak
Perne, Claudia
Strauss, Hans-Georg
Tecklenburg, Johanna
Holinski-Feder, Elke
Steinke-Lange, Verena
Mecklin, Jukka-Pekka
Plazzer, John-Paul
Pineda, Marta
Navarro, Matilde
Brunet Vidal, Joan
Kariv, Revital
Rosner, Guy
Alejandra Pinero, Tamara
Laura Gonzalez, Maria
Kalfayan, Pablo
Ryan, Neil
Ten Broeke, Sanne W.
Jenkins, Mark A.
Sunde, Lone
Bernstein, Inge
Burn, John
Greenblatt, Marc
Cappel, Wouter H. de Vos tot Nederveen
Della Valle, Adriana
Lopez-Koestner, Francisco
Alvarez, Karin
Buettner, Reinhard
Goergens, Heike
Morak, Monika
Holzapfel, Stefanie
Hueneburg, Robert
Doeberitz, Magnus von Knebel
Loeffler, Markus
Rahner, Nils
Weitz, Jurgen
Pylvanainen, Kirsi
Renkonen-Sinisalo, Laura
Lepisto, Anna
Auranen, Annika
Hopper, John L.
Win, Aung Ko
Haile, Robert W.
Lindor, Noralane M.
Gallinger, Steven
Le Marchand, Loic
Newcomb, Polly A.
Figueiredo, Jane C.
Thibodeau, Stephen N.
Therkildsen, Christina
Okkels, Henrik
Ketabi, Zohreh
Denton, Oliver G.
Rodland, Einar Andreas
Vasen, Hans
Neffa, Florencia
Esperon, Patricia
Tjandra, Douglas
Moeslein, Gabriela
Sampson, Julian R.
Evans, D. Gareth
Seppala, Toni T.
Moller, Pal

Abstract

Purpose To determine impact of risk-reducing hysterectomy and bilateral salpingo-oophorectomy (BSO) on gynecological cancer incidence and death in heterozygotes of pathogenic MMR (path_MMR) variants. Methods The Prospective Lynch Syndrome Database was used to investigate the effects of gynecological risk-reducing surgery (RRS) at different ages. Results Risk-reducing hysterectomy at 25 years of age prevents endometrial cancer before 50 years in 15%, 18%, 13%, and 0% of path_MLH1, path_MSH2, path_MSH6, and path_PMS2 heterozygotes and death in 2%, 2%, 1%, and 0%, respectively. Risk-reducing BSO at 25 years of age prevents ovarian cancer before 50 years in 6%, 11%, 2%, and 0% and death in 1%, 2%, 0%, and 0%, respectively. Risk-reducing hysterectomy at 40 years prevents endometrial cancer by 50 years in 13%, 16%, 11%, and 0% and death in 1%, 2%, 1%, and 0%, respectively. BSO at 40 years prevents ovarian cancer before 50 years in 4%, 8%, 0%, and 0%, and death in 1%, 1%, 0%, and 0%, respectively. Conclusion Little benefit is gained by performing RRS before 40 years of age and premenopausal BSO in path_MSH6 and path_PMS2 heterozygotes has no measurable benefit for mortality. These findings may aid decision making for women with LS who are considering RRS.

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1364930400
Document Type :
Electronic Resource